Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-05-09
2009-06-30
Gitomer, Ralph (Department: 1657)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S975000
Reexamination Certificate
active
07553824
ABSTRACT:
A kit for the determination of the ability of a peripheral blood mononuclear cell to bind to a polysaccharide herein provided comprises a detection reagent comprising a fluorescence-labeled immunostimulant polysaccharide; and a reference reagent comprising a fluorescence-labeled material of a polysaccharide different from that used in the fluorescence-labeled immunostimulant polysaccharide, and/or an immunostimulant polysaccharide which is not labeled with any fluorescent material and whose polysaccharide moiety is identical to that included in the fluorescence-labeled immunostimulant polysaccharide. The use of this kit would permit the estimation of the polysaccharide-binding ability of a peripheral blood mononuclear cell in a higher precision of estimation.
REFERENCES:
patent: 5106616 (1992-04-01), McAnalley et al.
patent: 5705398 (1998-01-01), Mintz et al.
patent: 6956120 (2005-10-01), Ikewaki et al.
patent: 2001/0051717 (2001-12-01), Wakshull et al.
patent: 2004/0132131 (2004-07-01), Markman et al.
patent: 2006/0160766 (2006-07-01), Cheung
patent: 2006/0188506 (2006-08-01), Cheung
patent: 2007/0031898 (2007-02-01), Suga et al.
patent: 04-024555 (1992-01-01), None
patent: 04-346791 (1992-12-01), None
Oka M. et al., “In Vitro and in Vivo Analysis of Human Leukocyte Binding by the Antitumor Polysaccharide, Lentinan”, Int. J. Immunopharmac., vol. 18, No. 3, pp. 211-216, (1996).
Suga T., et al., “Antitumor Activity of Lentinan in Murine Syngeneic and Autochthonous Hosts and Its Suppressive Effect on 3-Methylcholantherene-induced Carcinogenesis”,Cancer Research, Nov. 1984, vol. 44, pp. 5132-5137.
50thAnnual Mtg. Proc. Jpn., Cancer Assoc., 1991, pp. 259.
Vetvicka V., et al, “Soluble β-Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor Type 3 (CD11b/CD18) Generates a Primed State of the Receptor Capable of Mediating Cytotoxicity of iC3b-Opsonized Target Cells”,J. Clin Invest, Jul. 1996, vol. 98, No. 1, p. 50-61.
Brown G., et al., “Dectin-1 Is A Major β-Glucan Receptor On Macrophages”,J. Exp. Med, Aug. 5, 2002, vol. 196, No. 3, pp. 407-412.
Daniel J. Allendorf, et al., “macrophages suttle orally administered beta-glucan to potentiate the CR3-dependent tumoricidal effects of monoclonal antibodies in mouse tumor models”, Faseb Journal, FED. of American soc. for experimental biology, bethesda, MD, US, XP009099286, vol. 17, No. 7, May 10, 2003, p. C128.
Daniel J. Allendorf, et al. “Orally administered beta-glucan functions via anti-tumor mAbs and the complement system to recruit CR3+ neutrophils and macrophages that produce tumor regression and tumor-free survival”, Molecular Immunology, Elmsford, NY, US, XP 009099285, vol. 40, No. 2-4, Sep. 6, 2003, pp. 195-196.
Penagiotis Kougias, et al., “Normal human fibroblasts express pattern recognition receptors for fungal (1->3)-beta-D-glucans”, Infection and Immunity, XP002477857, vol. 69, No. 6,Jun. 2001, pp. 3933-3938.
Murata Masahiro
Suga Tetsuya
Suga Yasuyo
Ajinomoto Co. Inc.
Gitomer Ralph
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Kit for determining polysaccharide-binding activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kit for determining polysaccharide-binding activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kit for determining polysaccharide-binding activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4052970